- Amazon’s earnings are expected to continue growing robustly, driven by efficiency initiatives. The stock has underperformed the S&P 500 but is poised for a rebound. Agentic AI could boost Amazon Web Services in 2026.
- BeOne Medicines, with its flagship product Brukinsa, is an underrated biotech stock. It recently received Chinese regulatory approval for sonrotoclax and awaits U.S. approval. The company could file for accelerated approval of BGB-16673 for the treatment of R/R CLL.
- Enterprise Products Partners offers income investors a high distribution yield of 6.6% with consistent distribution increases. The construction of new data centers hosting AI applications is expected to drive growth in natural gas demand, benefiting the LP.
Read more at Nasdaq: 3 Stocks to Buy in February